between the two groups in each category, there was almost no difference up to category 0-C. However, in the cases improved to category 1-A or better, the survival period was longer in the TAE group.
The cumulative survival rate was compared among the four groups: TAE group, one-shot group, systemic administration group and no therapy group. As a result, in the TAE group, the one-year survival rate was 62%, and the twoyear survival rate was 42% (Fig. 2) survived two years, while 15 patients with portal obstruction all died within six months. When the survival rates of the TAE group and one-shot group (without portal obstruction) were compared, a significant difference was noted at 6, 12 and 18 months (respectively, P < 0.001, P < 0.001, P < 0.01). In the group with systemic administration of anticancer drugs, 20% survived one year and 6.7% two years, and the longest record was 3 years and four months in a case given FT-207. In the no therapy group, only two patients survived a year, but both died within two years.
Hence, the TAE was excellent in the degree of improvement of clinical findings as compared with one shot, and its prognosis was better than that of one-shot and other medical treatments.
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